GSK plc

GSK plc Total Assets

The Total Assets of GSK plc (GSK.L) as of Nov 12, 2026 is 61.12 B GBP. In the previous year, Total Assets was 59.46 B GBP — a change of 2.78% (higher).

Total Assets

61.12 BGBP

YoY

2.78%

Last updated:

Total Assets of GSK plc is 2025 61.12 B GBP. Total Assets of GSK plc was 2024 59.46 B GBP. It decreases by 2.78% higher compared to the previous year.

The GSK plc Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
58.07 B GBP
Jan 1, 2019
79.69 B GBP
Jan 1, 2020
80.43 B GBP
Jan 1, 2021
79.10 B GBP
Jan 1, 2022
60.15 B GBP
Jan 1, 2023
59.01 B GBP
Jan 1, 2024
59.46 B GBP
Jan 1, 2025
61.12 B GBP
The GSK plc Total Assets history
YEARTotal AssetsYoY
61.12 BGBP+2.78%
59.46 BGBP+0.78%
59.01 BGBP-1.90%
60.15 BGBP-23.96%
79.10 BGBP-1.65%
80.43 BGBP+0.93%
79.69 BGBP+37.24%
58.07 BGBP+2.99%
56.38 BGBP-4.57%
59.08 BGBP+10.54%
53.45 BGBP+31.48%
40.65 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Total Assets of GSK plc is 61.12 B GBP in 2025.

Total Assets of GSK plc changed from 59.46 B GBP to 61.12 B GBP, representing a 2.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets GSK plc since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc